According to relevant studies,cistanche is a traditional Chinese herb that has been used for centuries to treat various diseases. It has been scientifically proven to possess anti-inflammatory, anti-aging, and antioxidant properties. Studies have shown that cistanche is beneficial for patients suffering from kidney disease. The active ingredients of cistanche are known to reduce inflammation, improve kidney function and restore impaired kidney cells. Thus, integrating cistanche within a kidney disease treatment plan can offer great benefits to patients in managing their condition. Cistanche helps to reduce proteinuria, lowers BUN and creatinine levels, and decreases the risk of further kidney damage. In addition, cistanche also helps reduce cholesterol and triglyceride levels which can be dangerous to patients suffering from kidney disease.

Click on Cistanche Extract Powder

For more info: 

david.deng@wecistanche.com  WhatApp:86 13632399501

Cistanche's antioxidant and anti-aging properties help to protect the kidneys from oxidation and damage caused by free radicals. This improves kidney health and reduces the risks of developing complications. Cistanche also helps to boost the immune system, which is essential in fighting off kidney infections and promoting kidney health. By combining traditional Chinese herbal medicine and modern Western medicine, those suffering from kidney disease can have a more comprehensive approach to treating the condition and improving their quality of life. Cistanche should be used as part of a treatment plan but is not to be used as an alternative to conventional medical treatments.

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) posed a major threat to health care and medical staff from the start of the epidemic, but its impact will extend beyond this pandemic and into the future [1]. The kidney is one of the organs that has been infected with SARS-CoV-2. Podocytes, proximal renal tubular cells, glomerular endothelial cells, as well as perhaps mesangial cells and Bowman’s capsule epithelium, exhibit the essential angiotensin-converting enzyme type 2 (ACE2) for viral entry. The expression of ACE2 in the kidneys is extremely high, maybe 100 times higher than in the lungs [2]. Infected individuals have much higher levels of angiotensin 2 in their blood, which activates the renin–angiotensin system, causing extensive endothelial dysfunction [3]. Patients who have had coronavirus disease 2019 (COVID-19)-induced acute kidney injury (AKI) are not uncommon these days, and they have a significantly increased risk of developing progressive chronic kidney disease (CKD) as a result of their treatment. Mechanical breathing, continuous renal replacement treatment, and extracorporeal membrane oxygenation are frequently used to help patients with severe and critical COVID-19 [4]. AKI is detected in around 28% of COVID-19 patients who are hospitalized, and 9% of these patients who undergo kidney replacement treatment [5]. However, given the growing body of evidence, it appears that it is not just the survival of AKI associated with COVID-19 that can cause damage to kidney disease associated with COVID-19. COVID-19 increased the risk of CKD, according to United States research that utilized electronic health data from the Veterans Health Administration to conduct a complete evaluation of lengthy COVID-19. This risk was the largest among individuals who had severe illness. Even beyond the first 30 days after diagnosis of COVID-19, unfavorable renal symptoms such as urinary tract infections, AKI, and CKD occurred in individuals who required hospitalization [6]. Patients with COVID-19 in China indicated that 6 months after COVID-19 hospitalization, 35% of patients had impaired kidney function (estimated glomerular filtration rate [eGFR] < 90 mL/min/1.73 m2). Surprisingly, during follow-up, 13% of patients who did not develop AKI during hospitalization showed a decrease in eGFR [7]. In a study of more than 1.7 million persons, 90,000 of whom were COVID-19 survivors with symptoms lasting at least 30 days, it was shown that roughly 5% of them had a 30% drop in a vital measure of kidney function (eGFR). This means that those infected with LONG-COVID-19 were 25% more likely than uninfected people to acquire a 30% drop in eGFR, with a larger risk in those who survived the more severe sickness. However, the condition impacted many patients who were not hospitalized [8]. From the perspective of some studies, which indicate that 5% of vaccinated patients develop long-COVID-19, and in the unvaccinated group, 11% may pose a serious nephrology challenge during and after the pandemic itself, when we deal with a huge percentage of patients with ailments of the kidneys [9]. Clinicians who must pay close attention to kidney function evaluation will play a critical role, not only in the group of hospitalized patients but also in the group of seemingly asymptomatic patients, notably in the group of patients with LONG-COVID-19. Vaccinations also play an important role in reducing the risk of serious illness, hospitalization, and complications such as LONG-COVID-19. In the current epidemiological crisis, it is critical to vaccinate as many people as possible to protect them against the long-term impacts of complications from the pandemic. We must also remember that vaccinated people may also become ill, even mildly, and suffer complications even after an asymptomatic form of the disease, so remember to wear masks and social distance [10].

Conflict of interest: None declared

References

1. Dzieciatkowski T, Szarpak L, Filipiak KJ, et al. COVID-19 challenge for modern medicine. Cardiol J. 2020; 27(2): 175–183, doi: 10.5603/CJ.a2020.0055, indexed in Pubmed:32286679.

2. Huang Z, Jiang Y, Chen J, et al. Inhibitors of the renin-angiotensin system: The potential role in the pathogenesis of COVID-19. Cardiol J. 2020; 27(2): 171–174, doi: 10.5603/CJ.a2020.0056, indexed in Pubmed: 32286678.

3. Smereka J, Szarpak L, Filipiak K. Modern medicine in COVID-19 era. Dis Emerg Med J. 2020, doi: 10.5603/demj.a2020.0012.

4. Yu M, Cheng X. Cardiac injury is independently associated with mortality irrespective of comorbidity in hospitalized patients with coronavirus disease 2019. Cardiol J. 2020; 27(5): 472–473, doi: 10.5603/CJ.2020.0150, indexed in Pubmed: 33165894.

5. Silver SA, Beaubien-Souligny W, Shah PS, et al. The prevalence of acute kidney injury in patients hospitalized with COVID-19 infection: a systematic review and meta-analysis. Kidney Med. 2021; 3(1): 83–98.e1, doi: 10.1016/j.xkme.2020.11.008, indexed in Pubmed: 33319190.

6. Al-Aly Z, Xie Y, Bowe B. High-dimensional characterization of post-acute sequelae of COVID-19. Nature. 2021; 594(7862): 259–264, doi: 10.1038/s41586-021-03553-9, indexed in Pubmed: 33887749.

7. Huang C, Huang L, Wang Y, et al. 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. Lancet. 2021; 397(10270): 220–232, doi: 10.1016/S0140- 6736(20)32656-8, indexed in Pubmed: 33428867.

8. Bowe B, Xie Y, Xu E, et al. Kidney outcomes in long COVID. J Am Soc Nephrol. 2021; 32(11): 2851–2862, doi: 10.1681/ ASN.2021060734, indexed in Pubmed: 34470828.

9. Antonelli M, Penfold RS, Merino J, et al. Risk factors and disease profile of post-vaccination SARS-CoV-2 infection in UK users of the COVID Symptom Study app: a prospective, community-based, nested, case-control study. Lancet Infect Dis. 2021 [Epub ahead of print], doi 10.1016/S1473-3099(21)00460-6, indexed in Pubmed: 34480857.

10. Szarpak L, Smereka J, Filipiak KJ, et al. Cloth masks versus medical masks for COVID-19 protection. Cardiol J. 2020; 27(2): 218– –219, doi: 10.5603/CJ.a2020.0054, indexed in Pubmed: 32285928

For more info: david.deng@wecistanche.com  WhatApp:86 13632399501